CN108283632B - Composition and its application containing butyric acid compound - Google Patents
Composition and its application containing butyric acid compound Download PDFInfo
- Publication number
- CN108283632B CN108283632B CN201711217080.6A CN201711217080A CN108283632B CN 108283632 B CN108283632 B CN 108283632B CN 201711217080 A CN201711217080 A CN 201711217080A CN 108283632 B CN108283632 B CN 108283632B
- Authority
- CN
- China
- Prior art keywords
- butyric acid
- liver
- acid compound
- biliary atresia
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 title claims abstract description 116
- -1 butyric acid compound Chemical class 0.000 title claims abstract description 54
- 239000000203 mixture Substances 0.000 title claims abstract description 15
- 206010010317 Congenital absence of bile ducts Diseases 0.000 claims abstract description 52
- 201000005271 biliary atresia Diseases 0.000 claims abstract description 52
- 238000002360 preparation method Methods 0.000 claims abstract description 39
- 230000002265 prevention Effects 0.000 claims abstract description 18
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 54
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- JXPHLUCMHXXHEJ-UHFFFAOYSA-N 2-(aminomethyl)-4-bromoaniline Chemical compound NCC1=CC(Br)=CC=C1N JXPHLUCMHXXHEJ-UHFFFAOYSA-N 0.000 claims description 3
- FYPVXEILSNEKOO-UHFFFAOYSA-L calcium;butanoate Chemical compound [Ca+2].CCCC([O-])=O.CCCC([O-])=O FYPVXEILSNEKOO-UHFFFAOYSA-L 0.000 claims description 3
- PQLMXFQTAMDXIZ-UHFFFAOYSA-N isoamyl butyrate Chemical group CCCC(=O)OCCC(C)C PQLMXFQTAMDXIZ-UHFFFAOYSA-N 0.000 claims description 3
- RWMKSKOZLCXHOK-UHFFFAOYSA-M potassium;butanoate Chemical compound [K+].CCCC([O-])=O RWMKSKOZLCXHOK-UHFFFAOYSA-M 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 51
- 235000016709 nutrition Nutrition 0.000 abstract description 24
- 238000000034 method Methods 0.000 abstract description 20
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 7
- 239000000126 substance Substances 0.000 abstract description 6
- 238000011161 development Methods 0.000 abstract description 5
- 230000035935 pregnancy Effects 0.000 abstract description 5
- 208000024891 symptom Diseases 0.000 abstract description 3
- 210000004185 liver Anatomy 0.000 description 69
- 235000013350 formula milk Nutrition 0.000 description 29
- 241000700159 Rattus Species 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 27
- 235000013305 food Nutrition 0.000 description 23
- 230000001587 cholestatic effect Effects 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 210000000013 bile duct Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 238000004043 dyeing Methods 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 241000193171 Clostridium butyricum Species 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 13
- 206010008635 Cholestasis Diseases 0.000 description 12
- 230000004761 fibrosis Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 10
- 230000035764 nutrition Effects 0.000 description 10
- 206010019668 Hepatic fibrosis Diseases 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 230000002440 hepatic effect Effects 0.000 description 9
- 230000003908 liver function Effects 0.000 description 9
- 230000000750 progressive effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000003613 bile acid Substances 0.000 description 8
- 231100000359 cholestasis Toxicity 0.000 description 8
- 230000007870 cholestasis Effects 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000002603 extrahepatic bile duct Anatomy 0.000 description 7
- 230000007935 neutral effect Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 230000009977 dual effect Effects 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000003445 biliary tract Anatomy 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 102000014736 Notch Human genes 0.000 description 4
- 108010070047 Notch Receptors Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000002960 lipid emulsion Substances 0.000 description 4
- 208000018191 liver inflammation Diseases 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 206010061876 Obstruction Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000013248 bile duct ligation model Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 235000016236 parenteral nutrition Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010067470 Rotavirus infection Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003872 anastomosis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 150000004652 butanoic acids Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000004129 fatty acid metabolism Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000006676 mitochondrial damage Effects 0.000 description 2
- 230000007948 negative regulation of Notch signaling pathway Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 235000020601 preterm formula Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 206010056375 Bile duct obstruction Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010067508 Low birth weight baby Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 208000031816 Pathologic Dilatation Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020616 amino acid formula Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- BJUFAVXYJRJBLQ-UHFFFAOYSA-N butanoic acid;propane-1,2,3-triol Chemical compound CCCC(O)=O.OCC(O)CO BJUFAVXYJRJBLQ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940094941 isoamyl butyrate Drugs 0.000 description 1
- 235000020214 lactose-free milk formula Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention provides a kind of composition containing butyric acid compound and its application, the butyric acid compound can be used for preventing and treating Biliary atresia and its complication.The composition containing butyric acid compound, including butyric acid compound and nutritional preparation or excipient substance；The concentration of the butyric acid compound is 5~70mM.Innovative using of the invention is typically applied to the interference method of enteron aisle to prevent and treat Biliary atresia and its complication.Butyric acid compound is used directly for or is added in nutritional preparation the pregnancy and newborn individual being used for without any symptom as a kind of safe and effective control method, to fundamentally prevent and treat the occurrence and development of Biliary atresia.And the present invention solves Biliary atresia complication-liver fibrosis prevention and treatment technical problem simultaneously, provides a kind of safe, economic and effective method for the prevention and treatment of Biliary atresia liver fibrosis.
Description
Technical field
The present invention relates to food pharmaceutical technology fields, specifically, be related to a kind of composition containing butyric acid compound and
Its application in prevention and treatment Biliary atresia and its complication.
Background technique
Biliary atresia (biliary atresia, BA) is a kind of congenital characterized by the obstruction of extrahepatic duct progressive
Sex deviation, disease incidence 1/5000-1/8000.Most of BA infant does not usually have apparent symptom in a couple of days after life, with
Extrahepatic duct progressive obstruction, gradually show obvious jaundice, clay color stool.Portojejunal anastomosis is Biliary atresia
Preferred therapeutic scheme.However it is unobstructed even if successfully restoring bile duct by portojejunal anastomosis, after bile normal drainage, still
Progressive obstruction of bile duct can occur, liver fibrosis is caused to rapidly develop to cirrhosis.Such as without orthotopic liver transplantation, BA's is long-term
Survival rate is the first cause for leading to Lebertransplantationim im Kindesalter less than 30%.
The cause of disease and pathogenesis of Biliary atresia are still not clear, and are a great problems clinically.Due to the morning of Biliary atresia
Phase diagnosis is extremely difficult, is difficult to and the diseases such as newborn's cholestasis, INFANT HEPATITIS SYNDROME and virus hepatitis in neonatal period
Disease identifies, and infant usually requires that it is hard to have progressed to has severe fibrosis even liver when causing to make a definite diagnosis by can just make a definite diagnosis for a long time
Change.On the other hand, due to lacking effectively preventing means, without effective remedy measures being diagnosed as Biliary atresia, finally
Still need to Liver Transplantation for Treatment.
Therefore, the control measure of Biliary atresia is the problem of clinically urgent need to resolve.However, the morbidity crowd of Biliary atresia
For newborn, Biliary atresia is early diagnosed without effective method again at present, how in the newborn crowd of non-evident sympton
The generation of safe and effective prevention Biliary atresia? and how the infant for being diagnosed as Biliary atresia safely and effectively inhibits
The liver fibrosis of progressive? these problems be all presently, there are technical problem.
Butyric acid is the natural component in mammal milk, and one of the metabolite of intestinal flora in vivo.Butyric acid is made
For one kind of short chain fatty acids, played an important role in terms of maintaining enteron aisle normal physiological function.Currently, grinding about butyric acid
Study carefully and focuses primarily upon intestines problem, and there is not been reported for effect of the butyric acid in prevention and treatment Biliary atresia.
On the other hand, the concurrent liver fibrosis progression of Biliary atresia is very rapid, and development is that liver is hard usually within some months
Change, and clinically a big difficulty.Liver fibrosis is divided into number of different types, virus hepatitis, alcoholic hepatitis, non-alcoholic rouge
The a variety of causes such as fat liver and cholestasis can all lead to liver fibrosis.Different types of liver fibrosis, the cause of disease and pathogenesis
Difference, control measure are also entirely different.The concurrent liver fibrosis of Biliary atresia belongs to one kind of cholestatic liver fibrosis, mesh
Before there is no safely and effectively control measure.
Research confirms that butyric acid has protective effect to some intestines problems such as ulcerative colitis, inflammatory bowel disease, however
The effect of butyric acid is really not so in cholestatic disease.Research finds that the cholestatic disease caused by bile duct ligation is dynamic
In object model, liver declines the metabolic capability of fatty acid, and especially short chain fatty acids such as butyric acid etc. can not be decomposed metabolism, causes
Short-chain fat acid concentration increases, and may aggravate cholestatic liver disease (Reichen J, ect.Mechanisms of
impaired hepatic fatty acid metabolism in rats with long-term bile duct
ligation.Hepatology.1994May；19(5):1272-81)(ühl S,ect.Reversibility of
hepatic mitochondrial damage in rats with long-term cholestasis.J
Hepatol.1998Jun；28(6):1000-7).On the other hand, Notch signal path and bile duct cell hyperplasia are in progressive
It plays an important role in cholestatic liver fibrosis.And the researchs such as Zhang X discovery butyric acid is by promoting Notch signal path
And hepatic progenitor cell is divided into bile duct epithelial cell, to play the effect (Zhang for promoting cholestatic liver fibrosis
X,et a1.Inhibition of notch signaling pathway prevents cholestatic liver
fibrosis by decreasing the differentiation of hepatic progenitor cells in to
cholangiocytes.Lab Invest.2016Mar；96(3):350-60).Therefore, these results of study, short chain rouge are based on
Fat acid such as butyric acid is considered as an important factor for promoting cholestatic liver fibrosis.
Summary of the invention
The technical problem to be solved by the present invention is in view of the shortcomings of the prior art, provide a kind of group containing butyric acid compound
Close object and its application.
The present invention provides a kind of composition that can be used in preventing and treating Biliary atresia and its complication.It is especially provided to prevent
With the effect in treatment Biliary atresia and its complication liver fibrosis.
It is very effective to prevent the hair of Biliary atresia after innovative use butyric acid compound of the invention intervenes pregnant mouse
It is raw.Butyric acid compound is used directly for or is added in nutritional preparation to be used for as a kind of safe and effective control method
The pregnancy of non-evident sympton and newborn individual, to fundamentally prevent and treat the occurrence and development of Biliary atresia.
On the other hand, the complication liver fibrosis of Biliary atresia belongs to cholestatic liver fibrosis, and prevention and treatment is also very tired
It is difficult.Even if common anti-inflammatory drug can alleviate liver inflammation reaction, it can not but alleviate the process of liver fibrosis.And it is directed to bile
Effect of the drug of acid synthesis in cholestatic liver fibrosis is also very limited.Because of the cholestatics disease such as Biliary atresia
Sick extrahepatic duct obstruction persistently exists, and the degree of cholestasis is very serious in liver, and the concentration of bile acid is usually above just
Even tens times or more of more than ten times of constant value.Some drugs for inhibiting bile acid biosynthesis are the enabled synthesis for reducing bile acid, liver
In bile acid concentration be still higher than normal value decades of times.And research confirms in the cholestatics diseases such as Biliary atresia, liver is fine
The degree and bile acid levels and non-correlation of dimensionization, thus inhibit bile acid biosynthesis in prevention and treatment Biliary atresia liver fibrosis
It acts on very limited.
Research finds that in cholestatic disease animal model, liver declines the metabolic capability of fatty acid, causes short
The raising of chain fatty acid concentration may aggravate cholestatic liver disease (Reichen J, ect.Mechanisms of impaired
hepatic fatty acid metabolism in rats with long-term bile duct
ligation.Hepatology.1994 May；19(5):1272-81)( S,ect.Reversibility
of hepatic mitochondrial damage in rats with long-term cholestasis.J
Hepatol.1998 Jun；28(6):1000-7).But we carefully analyze discovery, and positive evidence card is had no in these researchs
Effect of the real butyric acid in progressive cholestatic liver fibrosis.On the other hand, the researchs such as Zhang X discovery sodium butyrate passes through
Notch signal path and hepatic progenitor cell is promoted to be divided into bile duct epithelial cell to play promotion cholestatic liver fiber
Effect (Zhang X, the et a1.Inhibition of notch signaling pathway prevents of change
cholestatic liver fibrosis by decreasing the differentiation of hepatic
progenitor cells in to cholangiocytes.Lab Invest.2016Mar；96(3):350-60).However,
The research confirms the effect of sodium butyrate only with experiment in vitro, and function and effect in vivo are not necessarily so.
Of the invention innovative is intervened using animal model of the butyric acid compound to cholestatic liver fibrosis
And treatment, overcome prior art prejudice, can very effective prevention and treatment Biliary atresia complication liver fibrosis, solve clinically
Problem.
Research confirms that the degree of the cholestatics disease liver fibrosis such as Biliary atresia and bile acid levels, inflammatory cell are soaked
The indexs such as profit, ALT, AST and non-correlation.Present invention firstly discovers that Th1 type cell proportion and liver in bile duct ligation model liver
Degree of fibrosis is positively correlated, and Th1 type cell plays an important role during promoting cholestatic liver fibrosis.It is using
After butyric acid compound is intervened or treated, Th1 type cell proportion is remarkably decreased.Butyric acid compound is inhibited by specificity
The ratio of liver Th1 type cell plays an important role in prevention and treatment Biliary atresia progressive liver fibrosis.
The purpose of the present invention is what is be achieved through the following technical solutions:
The present invention provides a kind of butyric acid compounds in preparation prevention and treatment Biliary atresia and its composition of complication
Purposes.
The present invention provides a kind of composition containing butyric acid compound, including butyric acid compound and nutritional preparation or
Excipient substance；The concentration of the butyric acid compound is 5~70mM (mmol/L).
Preferably, the concentration of the butyric acid compound is 15~45mM.
Preferably, the butyric acid compound is 0.5-7mmol/kg/d as the effective dose of drug.
It is highly preferred that the butyric acid compound is 1.5-4.5mmol/kg/d as the effective dose of drug.
Preferably, the butyric acid compound is selected from sodium butyrate, potassium butyrate, calcium butyrate, magnesium butyrate, butyric acid, butyric acid glycerol
At least one of ester, isoamyl butyrate.
Preferably, the butyric acid compound is selected from least one of sodium butyrate, glycerol monobutyralte, butyric acid.
Preferably, the nutritional preparation is selected from conventional formulation food, special medicine purposes formula food, parenteral nutrition system
At least one of agent, enteral nutrition preparation.
Preferably, the conventional formulation food include in babies ' formula milk powder, pregnancy period and nursing period formula milk at least
It is a kind of；The special medicine purposes formula food includes premature labor/low birth weight baby formula milk, lactose-free formula or low cream
Sugared formula milk, milk protein part hydrolyzed formulas milk powder, lactoprotein depth hydrolysis formula or amino acid formula milk, breast milk and baby
The hardening agent or nutritional supplement of youngster's formula food, be suitable for food intolerance, allergy, hepatopathy special formulation food,
At least one of disease or the formula food of dysfunction；The parenteral nutrition preparation includes fat emulsion injection, All-In-One
At least one of nutrient solution, intravenous fluid；The enteral nutrition preparation includes amino acid pattern enteral nutrition preparation, short peptide type
At least one of enteral nutrition preparation, whole protein type enteral nutrition preparation, assembly type enteral nutrition preparation.
The present invention also provides a kind of preparation methods of composition containing butyric acid compound, which is characterized in that the system
Preparation Method includes: that butyric acid compound is proportionally added into the nutritional preparation or excipient substance, is uniformly mixed.
Special medicine purposes formula food (Food for Special Medical Purpose, FSMP) is in order to full
Foot feeds the limited, special requirement of Disorder of Digestion and A orption, metabolic disorder or particular disease states crowd to nutrient or diet, specially
The formula food that door processing is formulated.Such product must under doctor or clinical nutrition's teacher guidance, it is individually edible or and its
His food is matched.Special medicine purposes formula food belongs to food for special foods.When target group can not feed commonly
Diet or when can not meet its nutritional need with ordinary meal, special medicine purposes formula food can be used as a kind of nutritional supplementation
Approach plays important nutritional support to treatment, rehabilitation and body function maintenance etc. and acts on.
Preferably, the excipient substance includes pharmaceutically acceptable carrier or excipient, such as lactose hydrous, crystallite
Cellulose, mannitol, sodium citrate, calcium phosphate, glycine, starch；Disintegrating agent such as crospovidone, copolyvidone, hydroxyl
Amylcose acetate sodium, croscarmellose sodium and specific composition silicate；Binder such as polyvinylpyrrolidone, hydroxypropyl
Ylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), sucrose, gelatin and Arabic gum etc..
Preferably, the butyric acid compound be butyric acid when, butyric acid compound by coating or it is coated in the form of add.
It should be noted that the administration form of butyric acid compound is inessential in the present invention, butyric acid compound will be contained and added
It adds to suitable for the formula milk of infant and pregnant and lying-in women, special medicine purposes formula food and other enterals, parenteral nutrition system
In agent or excipient substance, as long as the effect of prevention and treatment Biliary atresia and its complication can be achieved in application effective quantity.
As an alternative solution of formula food application, butyric acid compound of the invention can be used as replenishers application
Rather than it is integrated into formula food.For example, butyric acid compound can be with pill, tablet, capsule, caplet, powder, liquid or solidifying
The intake of glue form.For example, butyric acid compound can be absorbed with other nutritional supplements as breast milk replenishers combine.
Compared with prior art, the present invention have it is following the utility model has the advantages that
1, innovative the using of the present invention is typically applied to the interference method of enteron aisle to prevent and treat Biliary atresia.Using butyric acid
After class compound intervenes pregnant mouse, the very effective generation for having prevented and treated Biliary atresia.Butyric acid compound as it is a kind of safely, have
The control method of effect is used directly for or is added in nutritional preparation the pregnancy and newborn individual being used for without any symptom, from
And fundamentally prevent the generation of Biliary atresia.
2, research is thought at present, and in cholestatic disease animal model, liver declines the metabolic capability of fatty acid,
Cause the raising of short-chain fat acid concentration that may aggravate cholestatic liver disease；And sodium butyrate is by promoting Notch signal logical
Road and hepatic progenitor cell are divided into bile duct epithelial cell, to play the effect for promoting cholestatic liver fibrosis.This hair
It is bright to overcome prior art prejudice, using butyric acid compound intervention and cholestatic liver fibrosis is treated, as the result is shown mould
Type group shows as severe liver fibrosis, and 3 grades of degree of fibrosis, and intervention group and treatment group have no obvious liver fibrosis.Therefore, originally
Invention solves the technical problem of Biliary atresia complication liver fibrosis prevention and treatment, provides a kind of safe, economical and effectively prevents
Control method.
3, research confirms the degree of hepatic fibrosis and bile acid levels, inflammatory cell of the cholestatics diseases such as Biliary atresia
The indexs such as infiltration, ALT, AST and non-correlation.Present invention firstly discovers that in bile duct ligation model liver, Th1 type cell ratio
Example is positively correlated with degree of hepatic fibrosis, and Th1 type cell plays an important role in progressive liver fibrosis process.Using fourth
After acid compounds are intervened or treated, Th1 type cell proportion is remarkably decreased.Butyric acid compound inhibits liver by specificity
The ratio of dirty Th1 type cell plays an important role in prevention and treatment Biliary atresia progressive liver fibrosis.
4, the speed being metabolized in vivo due to butyric acid is very fast, and in order to preferably play the function and effect of butyric acid, we will
Butyric acid compound is added to makes butyric acid slowly enter body with nutritional preparation suitable for the nutritional preparation of specific crowd
It digests and assimilates, more efficient plays a role.Butyric acid compound is added to the pregnancy and new life suitable for non-evident sympton
In the nutritional preparation of body, the occurrence and development of Biliary atresia can be fundamentally prevented and treated.
Therefore, the nutritional preparation and drug for adding butyric acid compound be it is a kind of safely, effectively, feasible prevention and treatment biliary tract closes
Lock disease and its method of complication liver fibrosis.
Detailed description of the invention
Upon reading the detailed description of non-limiting embodiments with reference to the following drawings, other feature of the invention,
Objects and advantages will become more apparent upon:
Fig. 1 is bile duct ligation (BDL) model liver HE and Masson dyeing；Wherein Fig. 1 a is BDL model group liver HE dye
Color；Fig. 1 b is BDL model group liver Masson dyeing；Fig. 1 c is BDL+ sodium butyrate intervention (30mM) liver HE dyeing；Fig. 1 d is
BDL+ sodium butyrate intervention (30mM) liver Masson dyeing；Fig. 1 e is that BDL+ sodium butyrate treats (45mM) liver HE dyeing；Fig. 1 f
(45mM) liver Masson dyeing is treated for BDL+ sodium butyrate；Fig. 1 g is that BDL+ sodium butyrate treats (70mM) liver HE dyeing；Figure
1h is that BDL+ sodium butyrate treats (70mM) liver Masson dyeing.
Fig. 2 is bile duct ligation (BDL) model liver lymphocyte FCM analysis Th1 type cell proportion；Wherein Fig. 2 a
For BDL model group liver Th1 type cell proportion (black circle)；Fig. 2 b is the intervention of BDL+ sodium butyrate (30mM) liver Th1 type cell
Ratio (black circle)；Fig. 2 c is that BDL+ sodium butyrate treats (45mM) liver Th1 type cell proportion (black circle)；Fig. 2 d is BDL+ fourth
Sour sodium treats (70mM) liver Th1 type cell proportion (black circle)；Fig. 2 e is the liver of BDL model group and each sodium butyrate intervention group
Th1 type cell proportion statistics；Fig. 2 f is the liver Th1 type cell proportion statistics of BDL model group and each sodium butyrate treatment group.
Specific embodiment
The present invention is described in detail combined with specific embodiments below.Following embodiment will be helpful to the technology of this field
Personnel further understand the present invention, but the invention is not limited in any way.It should be pointed out that the ordinary skill of this field
For personnel, without departing from the inventive concept of the premise, several changes and improvements can also be made.These belong to the present invention
Protection scope.
Embodiment 1
Present embodiments provide a kind of babies ' formula milk powder and preparation method thereof of butyric acid containing coating, the method are as follows: will
Food-grade coating butyric acid be added babies ' formula milk powder in, be uniformly mixed to get.Coating butyric acid in the formula milk of the preparation
Concentration is 5mmol/L.
Embodiment 2
Present embodiments provide a kind of pregnant and lying-in women's formula milk and preparation method thereof containing sodium butyrate, the method are as follows: will
Food-grade sodium butyrate be added pregnant and lying-in women's formula milk in, be uniformly mixed to get.Sodium butyrate is dense in the formula milk of the preparation
Degree is 15mmol/L.
Embodiment 3
Present embodiments provide a kind of preterm formula milk powder and preparation method thereof containing glycerol monobutyralte, the method
Are as follows: will food-grade glycerol monobutyralte be added preterm formula milk powder in, be uniformly mixed to get.In the formula milk of the preparation
The concentration of glycerol monobutyralte is 20mmol/L.
Embodiment 4
Present embodiments provide a kind of fat emulsion injection and preparation method thereof containing sodium butyrate, the method are as follows: will infuse
Grade sodium butyrate is penetrated to be added in fat emulsion injection, be uniformly mixed to get.Sodium butyrate is dense in the fat emulsion injection of the preparation
Degree is 30mmol/L.
Embodiment 5
Present embodiments provide a kind of All-In-One nutrient solution and preparation method thereof containing sodium butyrate, the method are as follows: will infuse
Grade sodium butyrate is penetrated to be added in All-In-One nutrient solution, be uniformly mixed to get.Sodium butyrate is dense in the All-In-One nutrient solution of the preparation
Degree is 45mmol/L.
Embodiment 6
Present embodiments provide a kind of short peptide type enteral nutrition preparation and preparation method thereof containing glycerol monobutyralte, the side
Method are as follows: will food-grade glycerol monobutyralte be added short peptide type enteral nutrition preparation in, be uniformly mixed to get.The small peptide of the preparation
The concentration of glycerol monobutyralte is 55mmol/L in type enteral nutrition preparation.
Embodiment 7
Present embodiments provide a kind of special disease formula food and preparation method thereof containing sodium butyrate, the method are as follows:
Will food-grade sodium butyrate be added special disease formula food in, be uniformly mixed to get.The special disease formula food of the preparation
The concentration of middle sodium butyrate is 70mmol/L.
Embodiment 8
Present embodiments provide a kind of pharmaceutical composition containing butyric acid compound and excipient substance.
The butyric acid compound is selected from sodium butyrate, potassium butyrate, calcium butyrate, magnesium butyrate, butyric acid, glycerol monobutyralte, butyric acid
At least one of isopentyl ester.
The effective dose of the butyric acid compound is 0.5~7mmol/kg/d.
It further include its compatible other medicine class and pharmaceutically may be used in described pharmaceutical composition with the butyric acid compound
The carrier and/or auxiliary material of receiving.
Described pharmaceutical composition is pharmaceutically acceptable any dosage form.
The dosage form is pulvis, injection, capsule, tablet or oral solution.
The butyric acid compound be butyric acid when, butyric acid compound by coating or it is coated in the form of be added into drug.
Composition containing butyric acid compound made from above embodiments can effectively prevent Biliary atresia and its complication liver
Fibrosis.Its optimum effective dose prevented is 15-30mmol/L or 1.5~3mmol/kg/d；The optimum effective dose for the treatment of
For 30-45mmol/L or 3~4.5mmol/kg/d.
Animal experiment compliance test result:
1, Biliary atresia animal model is induced using rotavirus infection newborn mice to be verified
1.1 experimental animals and grouping
The SPF grades of pregnant mouse of pregnant 7 days BALB/C are purchased from the western Poole-Bi Kai experimental animal in Shanghai Co., Ltd.In Shanghai, traffic is big
The attached Xinhua Hospital animal experimental center of institute of studying medicine is raised, and modeling group, sodium butyrate intervention group and sodium butyrate treatment group are divided into:
Biliary atresia modeling group: it in pregnant 24 hours mouse postpartum, using rotation virus intraperitoneal injection newborn rat, carries out biliary tract and closes
Modeling is locked, newborn rat uses breast-feeding；14 days after modeling, peripheral blood, bile duct, liver, intestinal tissue is taken to be detected；
Sodium butyrate intervention group (45mM): sodium butyrate is added in water and feeds pregnant 7 days pregnant mouse until producing, in pregnant mouse postpartum
In 24 hours, using rotation virus intraperitoneal injection newborn rat, Biliary atresia modeling is carried out, newborn rat uses breast-feeding；Modeling
14 days afterwards, peripheral blood, bile duct, liver, intestinal tissue is taken to be detected；
Sodium butyrate treatment group (45mM): in pregnant 24 hours mouse postpartum, using rotation virus intraperitoneal injection newborn rat, gallbladder is carried out
Road is latched modeling, and sodium butyrate is added in water and feeds female rat, and newborn rat uses breast-feeding；14 days after modeling, periphery is taken
Blood, bile duct, liver, intestinal tissue are detected.
1.2 result
Biliary atresia modeling group: detecting extrahepatic bile ducts patency, as a result, it has been found that modeling group mouse extrahepatic bile ducts obstructs
Resistance is infiltrated with serious cholestasis, bile duct paraplasm and liver inflammation；
Sodium butyrate intervention group (45mM): detecting extrahepatic bile ducts patency, as a result, it has been found that sodium butyrate intervention group mouse
Extrahepatic bile ducts is unobstructed, it is seen that liver inflammation infiltration has no obvious cholestasis and bile duct proliferation；
Sodium butyrate treatment group (45mM): detecting extrahepatic bile ducts patency, as a result, it has been found that sodium butyrate treatment group mouse
Extrahepatic bile ducts is still unobstructed, it is seen that liver inflammation cellular infiltration has no obvious cholestasis and bile duct proliferation.
Therefore, our innovative use butyric acid compounds intervene pregnant mouse, very effective to have prevented and treated newborn rat biliary tract
The occurrence and development of locking are of great significance for the prevention and treatment of clinically Biliary atresia.
2, the effect in Biliary atresia liver fibrosis is verified using extrahepatic bile ducts ligation model
Since rotavirus infection model is not suitable for research liver fibrosis, we study biliary tract using bile duct ligation model
It is latched liver fibrosis.
2.1 experimental animal
Cleaning grade three week old Sprague-Dawley (SD) rat, male and female are unlimited, weight about 50g, are purchased from the western Poole-in Shanghai
Bi Kai experimental animal Co., Ltd.It is raised in Xinhua Hospital Attached to Medical School, Shanghai Jiaotong Univ.'s animal experimental center.
2.2 processing method
Bile duct ligation (BDL) model group: feeding rat using water and normal diet, carries out after 7 days to rat ductus choledochus double
It ligatures and is cut from centre again；Without administration, the 14th day overnight fasting takes blood to survey blood biochemistry.Liver and intestinal tissue are taken, is used
In subsequent experimental.It is fixed with neutral formalin and carries out histotomy, do H-E dyeing, Masson and immunohistochemistry detection respectively.
BDL+ sodium butyrate intervention group: sodium butyrate being added to the water and feeds rat, and butyric acid na concn is respectively 5mM, 15mM,
30mM, 45mM, dosage are respectively 0.5mmol/kg/d, 1.5mmol/kg/d, 3mmol/kg/d, 4.5mmol/kg/d.Feed 7
After it, dual ligation is carried out to rat ductus choledochus and is cut from centre.Postoperative 14th day overnight fasting takes blood to survey blood biochemistry.It takes
Liver and intestinal tissue are used for subsequent experimental.Fixed with neutral formalin and carry out histotomy, be respectively H-E dyeing,
Masson and immunohistochemistry detection.
BDL+ coating butyric acid intervention group: butyric acid being added to the water and feeds rat, and butyric acid density is respectively 5mM, 15mM,
30mM, 45mM, dosage are respectively 0.5mmol/kg/d, 1.5mmol/kg/d, 3mmol/kg/d, 4.5mmol/kg/d.Feed 7
After it, dual ligation is carried out to rat ductus choledochus and is cut from centre.Postoperative 14th day overnight fasting takes blood to survey blood biochemistry.It takes
Liver and intestinal tissue are used for subsequent experimental.Fixed with neutral formalin and carry out histotomy, be respectively H-E dyeing,
Masson and immunohistochemistry detection.
BDL+ glycerol monobutyralte intervention group: glycerol monobutyralte being added to the water and feeds rat, glycerol monobutyralte concentration difference
For 5mM, 15mM, 30mM, 45mM, dosage is respectively 0.5mmol/kg/d, 1.5mmol/kg/d, 3mmol/kg/d,
4.5mmol/kg/d.After feeding 7 days, dual ligation is carried out to rat ductus choledochus and is cut from centre.Postoperative fasting in 14th day
Night takes blood to survey blood biochemistry.Liver and intestinal tissue are taken, subsequent experimental is used for.It is fixed with neutral formalin and carries out histotomy,
H-E dyeing, Masson and immunohistochemistry detection are done respectively.
BDL+ sodium butyrate treatment group: dual ligation is carried out to rat ductus choledochus and is cut from centre.It opens within the 7th day after modeling
Beginning, sodium butyrate is added to the water and feeds rat, for successive administration to the 14th day, butyric acid na concn was respectively 15mM, 30mM, 45mM,
70mM, dosage are respectively 1.5mmol/kg/d, 3mmol/kg/d, 4.5mmol/kg/d, 7mmol/kg/d.Fasting in 14th day
Night takes blood to survey blood biochemistry.Liver and intestinal tissue are taken, subsequent experimental is used for.It is fixed with neutral formalin and carries out histotomy,
H-E dyeing, Masson and immunohistochemistry detection are done respectively.
BDL+ clostridium butyricum intervention group: clostridium butyricum being added to the water and feeds rat, and the viable count of clostridium butyricum is 1 ×
107-4×107CFU/mL, dosage are 1 × 109-4×109CFU/kg/d.After feeding 7 days, rat ductus choledochus is carried out dual
It ligatures and is cut from centre.Postoperative 14th day overnight fasting takes blood to survey blood biochemistry.Liver and intestinal tissue are taken, subsequent reality is used for
It tests.It is fixed with neutral formalin and carries out histotomy, do H-E dyeing, Masson and immunohistochemistry detection respectively.
BDL+ clostridium butyricum treatment group: dual ligation is carried out to rat ductus choledochus and is cut from centre.The 7th day after modeling
Start, clostridium butyricum is added to the water and feeds rat, for successive administration to the 14th day, the viable count of clostridium butyricum was 5 × 107-9×
107CFU/mL, dosage are 5 × 109-9×109CFU/kg/d.14th day overnight fasting takes blood to survey blood biochemistry.Take liver and intestines
Road tissue is used for subsequent experimental.It is fixed with neutral formalin and carries out histotomy, be H-E dyeing, Masson respectively and be immunized
Groupization detection.
2.3 result
Bile duct ligation (BDL) model group: animal blood serum liver function index ALT, AST, GGT, TBA, TBIL are significantly increased, liver
Dirty color is obviously turned to be yellow, rough, and quality is harder；There is severe liver fibrosis in liver organization, and degree of fibrosis reaches 3 grades
(Fig. 1 a, Fig. 1 b).The Th1 type cell proportion for promoting progression of fibrosis in BDL model group liver significantly increases, and mean value reaches 21.3%
(Fig. 2 a, Fig. 2 e).
BDL+ sodium butyrate intervention group:
Sodium butyrate intervention group (5mM): liver function index slightly reduces, and liver color is slightly turned to be yellow, and pathological staining is as the result is shown
Liver moderate liver fibrosis, 2 grades of degree of hepatic fibrosis, compared with BDL group, liver Th1 type cell proportion declines, and mean value is
12.7% (Fig. 2 e)；
Sodium butyrate intervention group (15mM): liver function index is substantially reduced, and liver color is red, and any surface finish is soft, disease
The reason coloration result display slight liver fibrosis of liver, 1 grade of degree of hepatic fibrosis, compared with BDL group, liver Th1 type cell proportion
It is decreased obviously, mean value is 6.9% (Fig. 2 e)；
Sodium butyrate intervention group (30mM): liver function index significantly reduces, and liver color is scarlet, and any surface finish is soft,
Liver has no obvious fibrosis (Fig. 1 c, Fig. 1 d) to pathological staining as the result is shown；And FCM analysis is the results show that promote fiber
The liver Th1 type cell proportion of change process is remarkably decreased and close to normal value, and mean value is 1.8% (Fig. 2 b, Fig. 2 e)；
Sodium butyrate intervention group (45mM): liver function index significantly reduces, and liver color is scarlet, and any surface finish is soft,
Pathological staining liver mild fibrosis as the result is shown, 1 grade of degree of hepatic fibrosis, liver Th1 type cell proportion mean value is down to 2.4%
(Fig. 2 e).
The result of coating butyric acid intervention group and glycerol monobutyralte intervention group and the result of sodium butyrate intervention group are almost the same.
BDL+ sodium butyrate treatment group:
Sodium butyrate treatment group (15mM): every liver function index reduces, and liver color is slightly yellow, and 2 grades of hepatic fibrosis-renal tubular ectasia syndrome degree,
Compared with BDL group, liver Th1 type cell proportion decline, mean value is 15.7% (Fig. 2 f)；
Sodium butyrate treatment group (30mM): every liver function index is substantially reduced, and liver color is redder, and quality is softer, liver
Slight liver fibrosis, 1 grade of degree of fibrosis, compared with BDL group, liver Th1 type cell proportion is decreased obviously, mean value 7.6%
(Fig. 2 f)；
Sodium butyrate treatment group (45mM): every liver function index significantly reduces, and liver color is scarlet, and surface is smooth, quality
Softness, liver have no obvious liver fibrosis (Fig. 1 e, Fig. 1 f)；Compared with BDL group, liver Th1 type cell proportion is remarkably decreased,
Value is down to 4.8% (Fig. 2 c, Fig. 2 f)；
Sodium butyrate treatment group (70mM): every liver function index significantly reduces, and liver color is scarlet, and surface is smooth, quality
Softness, liver mild fibrosis, 1 grade of degree of hepatic fibrosis (Fig. 1 g, Fig. 1 h), liver Th1 type cell proportion are down to 5.5% (figure
2d, Fig. 2 f).
BDL+ clostridium butyricum group:
Clostridium butyricum intervention group is as the result is shown: giving 1 × 107-4×107After CFU/mL clostridium butyricum active bacteria is intervened
Degree of hepatic fibrosis and the reduction of Th1 type cell proportion are not obvious, and degree of fibrosis is 2-3 grades；
Clostridium butyricum treatment group is as the result is shown: giving 5 × 107-9×107CFU/mL clostridium butyricum active bacteria is treated,
Degree of hepatic fibrosis and Th1 type cell proportion have no and are decreased obviously that degree of fibrosis is still 3 grades.
Therefore, give butyric acid compound to be intervened, the generation of Biliary atresia is not only effectively prevented, for biliary tract
The prevention and treatment of blockage complications liver fibrosis also has extraordinary effect；Especially after butyric acid na concn reaches 30mM-45mM, prevention and treatment
Effect is especially pronounced.BDL modeling group shows as severe liver fibrosis, and degree of fibrosis is 3 grades, and BDL intervention group and treatment group
Have no obvious liver fibrosis.Therefore illustrate that butyric acid compound can be used for preventing and treating Biliary atresia and its complication liver fibrosis.And
The function and effect of clostridium butyricum are not obvious, and at present hygiene department regulation only have lactobacillus, Bifidobacterium and streptococcus this
Three kinds of probiotics can be added in food safely, and only Bifidobacterium and lactobacillus can be with security applications in infant formula milk
In powder.What kind of clostridium butyricum can generate as a kind of active microorganism in vivo influences unclear, may there is safety
Hidden danger.
In conclusion butyric acid compound can effectively prevent Biliary atresia and its complication liver fibrosis.Butyric acid is to exist
With one of mammal milk short chain fatty acids, and from the point of view of the result of animal experiment, butyric acid compound is in the concentration
Administration, does not cause any damage and side effect to experimental animal, illustrates that its drug safety is higher in range.Butyric acid compound
There to be very big application prospect for preventing and treating Biliary atresia and its complication liver fibrosis.
Specific embodiments of the present invention are described above.It is to be appreciated that the invention is not limited to above-mentioned
Particular implementation, those skilled in the art can make a variety of changes or modify within the scope of the claims, this not shadow
Ring substantive content of the invention.In the absence of conflict, the feature in embodiments herein and embodiment can any phase
Mutually combination.
Claims (1)
1. a kind of purposes of butyric acid compound in preparation prevention and treatment Biliary atresia and its composition of complication；
The butyric acid compound is selected from sodium butyrate, potassium butyrate, calcium butyrate, magnesium butyrate, butyric acid, glycerol monobutyralte, butyric acid isoamyl
At least one of ester.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711217080.6A CN108283632B (en) | 2017-11-28 | 2017-11-28 | Composition and its application containing butyric acid compound |
| PCT/CN2018/084676 WO2019104936A1 (en) | 2017-11-28 | 2018-04-26 | Composition containing butyric acid compound and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711217080.6A CN108283632B (en) | 2017-11-28 | 2017-11-28 | Composition and its application containing butyric acid compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108283632A CN108283632A (en) | 2018-07-17 |
| CN108283632B true CN108283632B (en) | 2019-06-07 |
Family
ID=62831601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711217080.6A Expired - Fee Related CN108283632B (en) | 2017-11-28 | 2017-11-28 | Composition and its application containing butyric acid compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108283632B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108208177A (en) * | 2017-11-28 | 2018-06-29 | 上海交通大学医学院附属新华医院 | Composition and its application containing butyric acid compound |
| CN109276564A (en) * | 2018-03-09 | 2019-01-29 | 上海交通大学医学院附属新华医院 | Butyric acid compound is promoting the application in the activation of tissue endogenous retinal stem cells, proliferation and differentiation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107684554B (en) * | 2017-08-29 | 2019-02-22 | 上海市儿科医学研究所 | Application of the butyric acid compound in preparation prevention and treatment NEC drug |
| CN107736614A (en) * | 2017-08-29 | 2018-02-27 | 上海市儿科医学研究所 | Nutritional preparation containing butyric acid |
-
2017
- 2017-11-28 CN CN201711217080.6A patent/CN108283632B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN108283632A (en) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cohen et al. | The gastrointestinal manifestations of scleroderma: pathogenesis and management | |
| Mayer et al. | Management of short bowel syndrome in postoperative very low birth weight infants | |
| CN108283632B (en) | Composition and its application containing butyric acid compound | |
| CN107736614A (en) | Nutritional preparation containing butyric acid | |
| Matsuda et al. | Structure-related inhibitory activity of oleanolic acid glycosides on gastric emptying in mice | |
| JP2016527281A (en) | Application of andrographolide in pharmaceutical preparations for the treatment of inflammatory bowel disease, andrographolide enteric target micropellets and method for producing the same | |
| CN111265536B (en) | Antitumor composition containing rare ginsenoside Rk2, CK and PPT | |
| CN108853478A (en) | A kind of anthocyanidin complex tablet that colon cancer and/or carcinoma of the rectum immunotherapeutic effects can be improved | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| CN101014334B (en) | Inhibitor for the onset and progress of liver cancer to be used in hepatitis c virus-positive human liver cirrhosis patients | |
| CN108402371A (en) | A kind of prebiotic compositions that suitable person in middle and old age's constipation crowd takes | |
| US20170258820A1 (en) | Synthetic composition and method for promoting mucosal healing | |
| CN104839679A (en) | Medical formula food for people with heart disease | |
| JP2021526143A (en) | A mixture of HMOs for treating autoimmune diseases | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| CN107684554B (en) | Application of the butyric acid compound in preparation prevention and treatment NEC drug | |
| CN104839642A (en) | Ovarian cancer medicine formula food | |
| CN111870609A (en) | Intestinal flora regulator and application thereof | |
| CN104256656A (en) | Full-nutrition formulated food for fatty acid metabolic disorder | |
| CN108208177A (en) | Composition and its application containing butyric acid compound | |
| CN108523123A (en) | A kind of full nutritional support food of diabetes | |
| CN105029391A (en) | Medical formula food for pancreatic cancer | |
| CN108904484A (en) | A kind of purposes of progallin A | |
| CN114916661A (en) | Natural food composition and its application | |
| WO2019104936A1 (en) | Composition containing butyric acid compound and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190607 Termination date: 20201128 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |